Shenzhen Bioeasy Biotechnology (SZ:300942) Huachuang Securities·2025-11-19 08:12Investment Rating - The report maintains a "Recommendation" rating for the company with a target price of 15 yuan [2][8]. Core Insights - The company's performance trend is overall positive, with significant growth in revenue and net profit for the first three quarters of 2025. Revenue reached 186 million yuan, up 17.45% year-on-year, and net profit was 18 million yuan, up 362.49% year-on-year [2][8]. - The impact of the divestment of the IVD business is clearing, leading to a recovery in revenue growth and a significant increase in profit margins. The company expects continued growth driven by overseas expansion and new partnerships [8]. - The company has secured a major cooperation agreement with a global biotechnology giant, which is expected to enhance its overseas business and drive future revenue growth [8]. Financial Summary - For 2024A, total revenue is projected at 224 million yuan, with a year-on-year growth rate of -11.7%. By 2025E, revenue is expected to increase to 272 million yuan, reflecting a growth rate of 21.5% [4]. - The net profit for 2024A is estimated at 17 million yuan, with a significant increase to 25 million yuan in 2025E, representing a growth rate of 44.9% [4]. - The earnings per share (EPS) is projected to rise from 0.04 yuan in 2024A to 0.06 yuan in 2025E [4]. Business Development - The company is actively expanding its domestic and international business, with notable partnerships in the retail and food processing sectors. Collaborations with major clients like Hema Fresh and Kang Shifu are highlighted [8]. - The company is also pursuing government contracts in various provinces, enhancing its presence in the public sector [8].